Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CT-202 · 1 trial · 3 indications
Phase 1a will evaluate increasing doses of CT-202 based on the assessment of DLTs
ORR will be based on the overall response rate as assessed by Investigators according to RECIST v1.1
| Arm | Type | Description |
|---|---|---|
| Phase 1a | EXPERIMENTAL | Dose Escalation-Bayesian Optimal Interval (BOIN) Design with approximately 54 patients in dose escalation. |
| Phase 1b | EXPERIMENTAL | Phase 1b: Dose Expansion - participants will be evaluated in 4-6 cohorts at different doses and schedules of CT-202 |
| Name | Type | Description |
|---|---|---|
| CT-202 | DRUG | Nectin-4 bispecific |
Inclusion Criteria: * Participants with nectin-4-positive triple negative breast cancer, colorectal cancer, or urothelial cancer that have received standard therapies * Participants with measurable disease per RECIST 1.1 * ECOG 0, 1, or 2 and life expectancy of ≥ 12 weeks * Participants have adequa...
CT-202 is an investigational small molecule being developed for the treatment of Triple Negative Breast Cancer (TNBC). It is currently in Phase 1 clinical development, and the ongoing trial also includes participants with colorectal and urothelial cancers.
CT-202 is a Nectin-4 directed bispecific antibody, meaning it targets the Nectin-4 protein. This mechanism is being studied in the context of recurring Triple Negative Breast Cancer, colorectal cancer, and urothelial cancers.
CT-202 is being developed by Context Therapeutics Inc., a biopharmaceutical company listed on the stock exchange under the ticker symbol CNTX. The company is conducting a Phase 1 first-time-in-human study of this investigational drug.
CT-202 is in Phase 1 clinical development. It is an investigational drug, not yet approved by regulatory authorities. The ongoing Phase 1a/1b study is currently recruiting participants.
CT-202 is being studied in a Phase 1a/1b first-time-in-human trial with the identifier NCT07545122. This recruiting study is enrolling approximately 162 participants in Australia and is investigating the drug in Triple Negative Breast Cancer, colorectal cancer, and urothelial cancers.
Yes, CT-202 is described as a Nectin-4 directed bispecific antibody. This means it is designed to bind to Nectin-4, a protein involved in certain cancers, and is being evaluated for its safety and efficacy in a Phase 1 clinical trial.